Sponsors (22)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Requires private and public health plans to cover FDA‑approved pre‑exposure (PrEP) and post‑exposure (PEP) HIV prevention drugs and related services without cost‑sharing and mostly without prior authorization; creates federal grants and education campaigns to expand access; strengthens confidentiality for use of preventive services on family plans; bans discrimination by life, disability, and long‑term care insurers against people taking HIV prevention medication; requires data reporting and federal monitoring; and creates a private right of action for violations.
The bill substantially expands no‑cost access to HIV prevention, strengthens nondiscrimination and enforcement tools, and funds outreach and provider capacity—trading clear public‑health gains for increased federal spending, new administrative and compliance costs for insurers/providers, and some implementation and legal complexities.
People at risk of HIV (including Medicaid, Medicare, VA, TRICARE, IHS beneficiaries and many with private coverage) will get FDA‑approved prevention drugs and related labs/monitoring with no out‑of‑pocket costs, expanding affordable access across federal and private programs.
Preauthorization for HIV prevention drugs is prohibited (with a narrow therapeutically‑equivalent exception), which speeds patient access and reduces administrative delays for providers and patients.
People who take HIV‑prevention medication cannot be denied or limited in life, disability, or long‑term care insurance nor charged higher premiums solely because they use PrEP, protecting insurance access and affordability.
Insurers, plans, providers, and sponsors face new reporting, compliance, and system‑change obligations (data collection, masking confidentiality, implementing no‑cost coverage, changing utilization management) that will raise administrative costs—some of which may be passed to enrollees as higher premiums.
The bill authorizes multiple uncapped or broadly described appropriations (grants, campaigns, IHS support), increasing federal and state spending with potential taxpayer impact and budget tradeoffs.
States have varied implementation windows and enforcement roles, risking uneven and delayed access across states and potential confusion for beneficiaries depending on where they live.
Introduced March 4, 2026 by Tina Smith · Last progress March 4, 2026